Pharmaceuticals, Biotechnology and Life Sciences
Seattle Genetics’ results from the phase 2 of trial testing tisotumab vedotin to treat patients with relapsed or progressed metastatic cervical cancer, showed clinically meaningful and durable objective responses with a manageable safety profile.
Rocket Pharmaceuticals has received clearance from the U.S. Food and Drug Administration (FDA) for the Company’s Investigational New Drug (IND) application for RP-L401, its, lentiviral vector (LVV)-based gene therapy for the treatment of Infantile Malignant Osteopetrosis (IMO), a rare, severe monogenic bone resorption disorder.
NanoImaging Services (NIS) said on Thursday that it is opening a new facility in Boston to support its growing customer base requiring cryoEM for drug discovery and vaccine development applications. COVID-19 projects are receiving prioritization.
Piramal Enterprises Limited’s (PEL) Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO), has entered into an agreement with G&W Laboratories Inc. to acquire its solid oral dosage drug product manufacturing facility located in Sellersville, Pennsylvania. The transaction closure is subject to customary preclosing conditions.
Actinium Pharmaceuticals on Wednesday announced the pricing of its previously announced public offering with gross proceeds expected to be approximately $25.0 million.
Aveo expects the gross proceeds from the offering to be approximately $44.6 million.
Results Presented at the American Diabetes Association’s Virtual 80th Scientific Sessions KENILWORTH, N.J. & NEW YORK–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK),…
Vyripharm Biopharmaceuticals and Regis Technologies, Inc. Have Signed Off on a Master Drug Program Agreement for Expediting cGMP Manufacture of Our Antiviral Agents for Diagnostic Evaluation of COVID-19.
ViiV Healthcare Friday said that the US Food and Drug Administration (FDA) has approved Tivicay PD (dolutegravir) tablets for oral suspension, used combined with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in certain young patients.
Pacific Biosciences of California’s CEO Michael Hunkapiller, Ph.D. is retiring as Chief Executive Officer and President by the end of the year, while planning to remain on the Board of Directors.